ABIVAX Société Anonyme (EPA:ABVX)

Market Cap	7.87B
Revenue (ttm)	6.78M
Net Income (ttm)	-293.52M
Shares Out	75.57M
EPS (ttm)	-4.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	177,284
Average Volume	152,272
Open	99.00
Previous Close	104.20
Day's Range	92.40 - 100.80
52-Week Range	4.51 - 126.60
Beta	-0.11
RSI	44.60
Earnings Date	Dec 15, 2025

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 69
• Stock Exchange: Euronext Paris
• Ticker Symbol: ABVX

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.